Drug Trial Radar · NCT00553787
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
Last checked: Nov 19, 2026Latest source record: Sep 10, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,487
Actual
Start
Nov 2007
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- VIVUS LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Nov 6, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
Conditions
- Obesity
- Type 2 Diabetes
Interventions
VI-0521Drug
phentermine 15 mg and topiramate 92 mg, po once daily
VI-0521Drug
phentermine 7.5 mg and topiramate 46 mg, po once daily
VI-0521Drug
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Weight Loss From Baseline to Week 56Time frame: Baseline to 56 weeks
- Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCFTime frame: Baseline to 56 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Ridgefield, Connecticut
Research Site
New York, New York
Research Site
Durham, North Carolina
Research Site
Toledo, Ohio
Research Site
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.